[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-367969-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-367969-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","spatial-multi-omics-identifies-aggressive-prostate-cancer-signatures-highlighting-pro-inflammatory-chemokine-activity-in-the-tumor-microenvironment","Spatial multi-omics identifies aggressive prostate cancer signatures highlighting pro-inflammatory chemokine activity in the tumor microenvironment","","Understanding the tumor microenvironment (TME) that drives aggressive prostate cancer (PCa) is essential for accurate diagnosis and treatment. Spatially resolved multi-omics data were interrogated to identify molecular stratifiers of aggressive PCa, yielding an aggressive prostate cancer (APC) gene expression signature predicting higher relapse and metastasis risk in 1,588 patients. A chemokine-enriched-gland (CEG) signature characterizes non-cancerous prostatic glands via pro-inflammatory chemokine upregulation, club-like cell enrichment, immune infiltration, metabolic changes, and loss of normal secretory function.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/spatial-multi-omics-identifies-aggressive-prostate-cancer-signatures-highlighting-pro-inflammatory-chemokine-activity-in-the-tumor-microenvironment/367969/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/spatial-multi-omics-identifies-aggressive-prostate-cancer-signatures-highlighting-pro-inflammatory-chemokine-activity-in-the-tumor-microenvironment/367969.png","ImageObject",300,407,{"name":42,"@type":43},"awa","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main goal of the study on aggressive prostate cancer?","Question",{"text":63,"@type":64},"To understand TME characteristics linked to aggressive prostate cancer by using spatially resolved multi-omics data to find molecular stratifiers.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What does the APC gene expression signature predict?",{"text":68,"@type":64},"It predicts increased risk of relapse and metastasis in a cohort of 1,588 patients.",{"name":70,"@type":61,"acceptedAnswer":71},"What defines the chemokine-enriched-gland (CEG) signature?",{"text":72,"@type":64},"Upregulated pro-inflammatory chemokines, club-like cell enrichment, and immune cell infiltration of surrounding stroma in non-cancerous prostatic glands.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},367969,1790471734,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},3985747858093,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","| |  |  | |\n| --- | --- | --- | --- |\n| Article [https://doi.org/10.1038/s41467-025-65161-9](https://doi.org/10.1038/s41467-025-65161-9) |  |  |  |\n| Spatial multi-omics identiﬁes aggressive prostate cancer signatures highlighting proinﬂammatory chemokine activity in the tumor microenvironment |  |  |  |\n| Received: 16 July 2024\u003Cbr>Accepted: 3 October 2025 Check for updates | Sebastian Krossa 1,2 , Maria K. Andersen 1,3, Elise M. Sandholm1,3, Maximilian Wess 1, Antti Kiviaho 4, Abhibhav Sharma 1,5, Sini Hakkola4, Yangyang Hao6, Mohammed Alshalalfa6, Elai Davicioni6, Trond Viset7,Øystein Størkersen7, R. Jeffrey Karnes8, Daniel E. Spratt 9,\u003Cbr>Guro F. Giskeødegård 5, Matti Nykter 4,10, Morten B. Rye3,11,\u003Cbr>Alfonso Urbanucci4,12 & May-Britt Tessem 1,3 \u003Cbr>Understanding the characteristics of the tumor microenvironment (TME) associated with aggressive prostate cancer (PCa) is essential for accurate diagnosis and treatment. We interrogated spatially resolved multi-omics data to ﬁnd molecular stratiﬁers of aggressive PCa. We report an aggressive prostate cancer (APC) gene expression signature predictive of increased risk of relapse and metastasis in a cohort of 1,588 patients. Further, we present achemokine-enriched-gland (CEG) signature speciﬁc to non-cancerous prostatic glands from patients with aggressive cancer. The CEG signature is characterized by upregulated expression of pro-inﬂammatory chemokines, club-like cell enrichment, and immune cell inﬁltration of surrounding stroma. The activity ofboth signatures is correlated with reduced citrate and zinc levels and loss of normal prostate secretory gland functions. In summary we report that an increased inﬂammatory status linked to chemokine production, clublike cell enrichment, and metabolic changes in normal-appearing prostatic glands is associated with the subsequent development of aggressive PCa. |  |  |\n| Prostate cancer (PCa) is the most common malignancy among men in western countries1. This disease is clinically, morphologically, and molecularly highly heterogeneous, which determines aggressiveness and clinical outcome2. Approximately 30% of PCa patients experience |  | relapse after prostatectomy and improving patient stratiﬁcation based on clinical and molecular parameters is an ongoing effort3. In search for biomarkers that are predictive of aggressiveness, substantial efforts are put into analyzing human PCa tissue having resulted in |  |\n\n1Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway. 2Central Staff, St. Olavs Hospital HF, Trondheim, Norway. 3Clinic of Surgery, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway. 4Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and TAYS Cancer Center, Tampere, Finland. 5HUNT Center for Molecular and Clinical Epidemiology, Department of Public Health and Nursing, Norwegian University of Science and Technology (NTNU), Trondheim, Norway. 6Veracyte, San Diego, CA, USA. 7Department of Pathology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway. 8Department of Urology, Mayo Clinic, Rochester, MN, USA. 9UH Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA. 10Foundation for the Finnish Cancer Institute, Helsinki, Finland. 11Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway. 12Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway. e-mail: [sebastian.krossa@ntnu.no](sebastian.krossa@ntnu.no); [may-britt.tessem@ntnu.no](may-britt.tessem@ntnu.no)  \ntissue-based biomarker assays such as Decipher and Prolaris4. More recently, to capture the transcriptomic heterogeneity, single-cell and spatial transcriptomics (ST) have emerged as popular technologies to study PCa tissue samples5–8. ST has the advantage of capturing transcriptomics proﬁles in hundreds and thousands of ","cbCainVy1OaDW91M","https://ap.wps.com/l/cbCainVy1OaDW91M","pdf",3147418,21,"English","# Background\n## Tumor microenvironment and aggressive prostate cancer\n## Need for predictive biomarkers\n## Spatial and single-cell transcriptomics\n## Inflammation, club cells, and chemokine activity\n# Study approach and key findings\n## APC gene expression signature and clinical outcome prediction\n## CEG signature in non-cancerous glands","[{\"question\":\"What is the main goal of the study on aggressive prostate cancer?\",\"answer\":\"To understand TME characteristics linked to aggressive prostate cancer by using spatially resolved multi-omics data to find molecular stratifiers.\"},{\"question\":\"What does the APC gene expression signature predict?\",\"answer\":\"It predicts increased risk of relapse and metastasis in a cohort of 1,588 patients.\"},{\"question\":\"What defines the chemokine-enriched-gland (CEG) signature?\",\"answer\":\"Upregulated pro-inflammatory chemokines, club-like cell enrichment, and immune cell infiltration of surrounding stroma in non-cancerous prostatic glands.\"}]","Spatial multi-omics identifies aggressive prostate cancer signatures highlighting pro-inflammatory chemokine activity in the tumor microenvironment | PDF",1790173985,53,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/15f52e5c3d0ff29feec109bcf7f3ef40.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/20ecf3900a19e0f70fd00af114e90f85.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/383d199739131d423a84f55eaeb2d5a6.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ed07fb95b310afeac9477d04b73a478e.webp",980,1301]